Evidence map›Paper›PMID 40374598›Full record

ArticleNature communications2025

Multi-institutional atlas of brain metastases informs spatial modeling for precision imaging and personalized therapy.

Jorge Barrios, Evan Porter, Dante P I Capaldi, Taman Upadhaya, William C Chen, Julian R Perks, Aditya Apte, Michalis Aristophanous, Eve LoCastro, Dylan Hsu and 36 more

Erratum issuedAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. An MRI Atlas of Regional Brain Vulnerability to Metastatic Disease.medRxiv : the preprint server for health sciences · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

46 authors.

Jorge Barrios *Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Evan Porter *Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Dante P I CapaldiDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Taman UpadhayaDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
William C ChenDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-8924-5853
Julian R PerksDepartment of Radiation Oncology, University of California Davis Health, Sacramento, CA, USA.
Aditya ApteDepartment of Radiation Oncology, Memorial Sloan Kettering, New York, NY, USA.
Michalis AristophanousDepartment of Radiation Oncology, Memorial Sloan Kettering, New York, NY, USA.
Eve LoCastroDepartment of Radiation Oncology, Memorial Sloan Kettering, New York, NY, USA.ORCID http://orcid.org/0000-0003-3975-8153
Dylan HsuDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Payton H StoneDepartment of Radiation Oncology, University of California Davis Health, Sacramento, CA, USA.
Javier E Villanueva-MeyerDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Gilmer ValdesDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Fei JiangDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.
Michael MaddalenaRadiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0003-1993-5271
Ase BallangrudDepartment of Radiation Oncology, Memorial Sloan Kettering, New York, NY, USA.ORCID http://orcid.org/0000-0001-8269-8921
Kayla PrezelskiDepartment of Radiation Oncology, Memorial Sloan Kettering, New York, NY, USA.
Hui LinDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-7356-3611
Jinger Y SunDepartment of Radiation Oncology, University of California Davis Health, Sacramento, CA, USA.
Muhtada A K AldinDepartment of Radiation Oncology, University of California Davis Health, Sacramento, CA, USA.
Oi Wai ChauDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Benjamin ZiemerDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Maasa SeabergDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-7655-1111
Penny K SneedDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Jean L NakamuraDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Lauren C BoretaDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Shannon E FoghDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
David R RaleighDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-9299-8864
Jessica ChewDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Harish VasudevanDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-9633-1100
Soonmee ChaDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Christopher HessDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Ruben FragosoDepartment of Radiation Oncology, University of California Davis Health, Sacramento, CA, USA.
David B ShultzDepartment of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Luke PikeDepartment of Radiation Oncology, Memorial Sloan Kettering, New York, NY, USA.ORCID http://orcid.org/0000-0001-9622-7442
Shawn L Hervey-JumperDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-4699-260X
Derek S TsangRadiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-9762-6901
Philip TheodosopoulosDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Daniel CookeDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Stanley H BenedictDepartment of Radiation Oncology, University of California Davis Health, Sacramento, CA, USA.
Ke ShengDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-6696-5409
Jan SeuntjensRadiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Catherine CoolensRadiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Joseph O DeasyDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0002-9437-266X
Steve BraunsteinDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Olivier MorinDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA. Olivier.Morin@ucsf.edu.ORCID http://orcid.org/0000-0002-9240-5704

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Brain metastases are a frequent and debilitating manifestation of advanced cancer. Here, we collect and analyze neuroimaging of 3,065 cancer patients with 13,067 brain metastases, representing an extensive collection for research. We find that metastases predominantly localize to high perfusion areas near the grey-white matter junction, but also identify notable differences depending on the primary cancer histology as well as brain regions which do not conform to this relationship. Lung and breast cancers, in contrast to melanoma, frequently metastasize to the cerebellum, hinting at biological pathways of spread. Additionally, the deep brain structures are relatively spared from metastasis, regardless of primary cancer type. Leveraging this data, we propose a probabilistic brain metastasis risk model to enhance the therapeutic ratio of whole-brain radiotherapy by targeting high risk areas while preserving cortical and subcortical brain regions of functional significance and low metastasis risk, potentially reducing the cognitive side effects of therapy.

Indexed as

Brain NeoplasmsNeuroimagingPrecision MedicineAdultAgedAtlases as TopicBrainBreast NeoplasmsFemaleHumansMagnetic Resonance ImagingMaleMiddle Aged

Identifiers

PMID40374598
PMCPMC12081687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.